Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study

References

• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–e93.
   PubMed Web of Science ®Google Scholar
• Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia. Haematologica. 2013;98:1826–1835.
   PubMed Web of Science ®Google Scholar
• Pizzo PA, Robichaud KJ, Gill FA, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med. 1979;67:194–200.
   PubMed Web of Science ®Google Scholar
• Schimpff S, Satterlee W, Young VM, et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284:1061–1065.
   PubMed Web of Science ®Google Scholar
• Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The international antimicrobial therapy cooperative group of the European organization for research and treatment of cancer. Antimicrob Agents Chemother. 1995;39:445–452.
   PubMed Web of Science ®Google Scholar
• Tamura K, Matsuoka H, Tsukada J, et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study. Am J Hematol. 2002;71:248–255.
   PubMed Web of Science ®Google Scholar
• Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003;37:382–389.
   PubMed Web of Science ®Google Scholar
• Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2013;6:CD003038.
   PubMed Web of Science ®Google Scholar
• Paul M, Dickstein Y, Borok S, et al. Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev. 2014;1:CD003914.
   Google Scholar
• de Marie S, van den Broek PJ, Willemze R, et al. Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination. Eur J Clin Microbiol Infect Dis. 1993;12:897–906.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, Villarroel M, Avendaño LF, et al. Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study. Clin Infect Dis. 1997;25:92–97.
   PubMed Web of Science ®Google Scholar
• Slobbe L, Waal L, Jongman LR, et al. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study. Eur J Cancer. 2009;45:2810–2817.
   PubMed Web of Science ®Google Scholar
• Gea-Banacloche J. Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies. Hematology Am Soc Hematol Educ Program. 2013;2013:414–422.
   PubMedGoogle Scholar
• Nesher L, Rolston KVI. Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis. 2013;56:711–717.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Bruzzi P, Glauser M. An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer. 1995;31A:2013–2022.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis. 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar
• Aguilar-Guisado M. Empirical antimicrobial therapy withdrawal after 72 hours of apyrexia in hematological patients with febrile neutropenia is safe and reduce unnecessary antibiotic exposure: final results of randomized clinical trial How Long. Abstract OS0250I [Internet]. ESCMID. 2017
   Google Scholar
• Santolaya ME, Alvarez AM, Acuña M, et al. Efficacy and safety of withholding antimicrobial treatment in children with cancer, fever and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial. Clin Microbiol Infect. 2017;23:173–178.
   PubMed Web of Science ®Google Scholar
• van der Velden WJFM, Herbers AHE, Netea MG, et al. Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis. Br J Haematol. 2014;167:441–452.
   PubMed Web of Science ®Google Scholar
• Wennerås C, Hagberg L, Andersson R, et al. Distinct inflammatory mediator patterns characterize infectious and sterile systemic inflammation in febrile neutropenic hematology patients. PLoS One. 2014;9:e92319.
   PubMed Web of Science ®Google Scholar
• Hodgson-Viden H, Grundy PE, Robinson JL. Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatr. 2005;5:10–16.
   PubMedGoogle Scholar
• Cherif H, Björkholm M, Engervall P, et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis. 2004;36:593–600.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014; 68:321–331.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–3051.
   PubMed Web of Science ®Google Scholar
• Nam EY, Song K-H, Kim N-H, et al. Differences in characteristics between first and breakthrough neutropenic fever after chemotherapy in patients with hematologic disease. Int J Infect Dis. 2016;44:4–7.
   PubMed Web of Science ®Google Scholar
• Micol J-B, Chahine C, Woerther P-L, et al. Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: is it ethical? Clin Microbiol Infect. 2014;20:O453–O455.
   PubMed Web of Science ®Google Scholar
• Cannas G, Pautas C, Raffoux E, et al. Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leuk Lymphoma. 2012;53:1068–1076.
   PubMed Web of Science ®Google Scholar
• Gyssens IC, Kern WV, Livermore DM. ECIL-4, a joint venture of EBMT, EORTC, ICHS and ESGICH of ESCMID. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica. 2013;98:1821–1825.
   PubMed Web of Science ®Google Scholar
• WHO. 2016_guidelines_web.pdf [Internet]. 2016. [cited 2016 Feb 14]. Available from: http://www.whocc.no/filearchive/publications/2016_guidelines_web.pdf
   Google Scholar
• InVS. Surveillance en incidence/Surveillance des infections associées aux soins (IAS)/Infections associées aux soins/Maladies infectieuses/Dossiers thématiques/Accueil [Internet]. 2016. [cited 2016 Feb 21]. Available from: http://www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Infections-associees-aux-soins/Surveillance-des-infections-associees-aux-soins-IAS/Surveillance-en-incidence
   Google Scholar
• Wu C-T, Chen C-L, Lee H-Y, et al. Decreased antimicrobial resistance and defined daily doses after implementation of a clinical culture-guided antimicrobial stewardship program in a local hospital. J Microbiol Immunol Infect. 2015;S1684–S1182.
   Google Scholar
• Jehl F, CASFM. Société Française de Microbiologie [Internet]. 2017. [cited 2017 May]. Available from: http://www.sfm-microbiologie.org/page/page/showpage/page_id/90.html.
   Google Scholar